Archives202520242023202220212020201920182017201620152014201320122011 September 01, 2020TR1 – Notification of major interest in shares by Lanstead Capital Read More July 27, 2020Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More June 18, 20202020 Annual General Meeting – all Resolutions Passed Read More June 16, 2020Total Share Capital Notification Read More June 11, 2020ImmuPharma PLC (“ImmuPharma” or the “Company”) Director/PDMR Shareholding Read More June 11, 2020Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline Read More June 05, 2020Notification of Change of Registered Office Address Read More June 02, 2020Notification of Change of AGM Venue Read More May 21, 2020Notice of AGM and posting of Report & Accounts Read More May 18, 2020TR1 – Notification of major interest in shares by Lanstead Capital Read More May 14, 2020ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka Read More April 30, 2020Audited Report & Accounts published on website Read More 1…1011121314…24
July 27, 2020Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients Read More
June 11, 2020Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline Read More
